Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours

Ocular Oncology

Genetic Analysis of Uveal Melanoma in 658 Patients Using the Cancer Genome Atlas Classification of Uveal Melanoma as A, B, C, and D

Ophthalmology.

Vichitvejpaisal P, Dalvin LA, Mazloumi M, Ewens KG, Ganguly A, Shields CL

doi: 10.1016/j.ophtha.2019.04.027.

Ocular Oncology

Impact of uveal melanoma thickness on post-plaque radiotherapy outcomes in the prophylactic anti-vascular endothelial growth factor era in 1131 patients

Clin Exp Ophthalmol.

Yang X, Dalvin LA, Mazloumi M, Chang M, Shields JA, Mashayekhi A, Shields CL

doi: 10.1111/ceo.13758.

Ocular Oncology

Robotic assisted CyberKnife radiosurgery for the treatment of iris melanoma

Sci Rep

Schmelter V, Heidorn S, Muacevic A, Priglinger SG, Foerster P, Liegl R

doi: 10.1038/s41598-021-84290-x

Ocular Oncology

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Eur J Cancer.

Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C

doi: 10.1016/j.ejca.2017.05.038.

Glaucoma and Ocular PressureOcular Oncology

Salvage proton beam therapy for recurrent iris melanoma: outcome and side effects

Graefes Arch Clin Exp Ophthalmol.

Riechardt AI, Klein JP, Cordini D, Heufelder J, Rehak M, Seibel I, Joussen AM

doi: 10.1007/s00417-018-3929-5.

Ocular Oncology

Genetic prognostication in uveal melanoma

Acta Ophthalmol.

Dogrusöz M, Jager MJ

doi: 10.1111/aos.13580.

Macular DiseasesOcular OncologyRetinal Diseases

Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients

Br J Ophthalmol.

Dalvin LA, Zhang Q, Hamershock RA, Chang M, Yu MD, Mashayekhi A, Shields CL

doi: 10.1136/bjophthalmol-2019-314686.

Ocular Oncology

A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes

Br J Ophthalmol.

Binkley E, Triozzi PL, Rybicki L, Achberger S, Aldrich W, Singh A

doi: 10.1136/bjophthalmol-2019-314461.

Ocular Oncology

Optimising prediction of early metastasis-free survival in uveal melanoma using a four-category model incorporating gene expression profile and tumour size

Br J Ophthalmol

Roelofs KA, Grewal P, Lapere S, Larocque M, Murtha A, Weis E

doi: 10.1136/bjophthalmol-2020-317714

Related content

Genetic Analysis of Uveal Melanoma in 658 Patients Using the Cancer Genome Atlas Classification of Uveal Melanoma as A, B, C, and D

Impact of uveal melanoma thickness on post-plaque radiotherapy outcomes in the prophylactic anti-vascular endothelial growth factor era in 1131 patients

Robotic assisted CyberKnife radiosurgery for the treatment of iris melanoma

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Salvage proton beam therapy for recurrent iris melanoma: outcome and side effects

Genetic prognostication in uveal melanoma

Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients

A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes

Optimising prediction of early metastasis-free survival in uveal melanoma using a four-category model incorporating gene expression profile and tumour size